Animal-origin-free cell dissociation is easy to specify and hard to document. For a cell or gene therapy process, the enzyme that releases your cells is an ancillary material — it touches the product, it does not appear in the final formulation, and your regulator will nonetheless expect a file on it. This note sets out what that file has to contain, what a current recombinant dissociation enzyme actually provides, and where the gaps still are.
Your dissociation enzyme is an ancillary material, not a consumable
The distinction is not semantic. A consumable is something you buy; an ancillary material is something you qualify. Reagents used during manufacture of a cell-based product but not intended to be present in the final product still carry risk — of adventitious agents, of residual carryover, and of lot-to-lot variability that propagates into your product's critical quality attributes. Reviews of cell-based product formulation have made the point that these “unintended components” are a recognised regulatory concern rather than an administrative footnote (Atouf, AAPS J 2016), and the same theme recurs in pharmaceutical-development assessments of cell-based medicinal products (Jere et al., J Pharm Sci 2020).
Practically, that means a dissociation enzyme needs a supplier file, a risk assessment, a specification you have agreed to, and a change-notification route — before it goes near a clinical batch.
Three frameworks your assessor will use — and they do not agree
Three documents govern ancillary materials for cell and gene therapy, and they are not interchangeable:
- Ph. Eur. 5.2.12 — Raw materials of biological origin for the production of cell-based and gene therapy medicinal products. The European general chapter; risk-based, and explicit about materials of biological origin.
- USP <1043> — Ancillary Materials for Cell, Gene, and Tissue-Engineered Products. The US general chapter, built around a risk-tiered qualification approach.
- ISO 20399:2022 — Biotechnology — Ancillary materials present during the production of cellular therapeutic products and gene therapy products. The consolidated international standard, replacing the three-part ISO/TS 20399 series of 2018, and the one that speaks directly to supplier obligations as well as user obligations.
A direct comparison of these guidelines found meaningful differences in scope and expectation between them (Tanaka et al., Cytotherapy 2022). The operational implication is simple: satisfying one does not automatically satisfy the others. If you file in both the EU and the US, check your supplier package against both chapters, not whichever one your supplier happens to cite.
Alongside these sits the transmissible spongiform encephalopathy question. Source selection remains the primary control for TSE agents in biologicals, because robust clearance methods are still developing (Farshid et al., Curr Opin Biotechnol 2005). An animal-origin-free enzyme addresses this at source rather than by clearance — which is why an AOF/TSE-BSE declaration is the first document to ask for, not the last.
The document pack: what to request before you qualify a dissociation enzyme
Use this as a request list to your supplier. The right-hand column shows what c-LEcta publishes for CellTrypase as of PIS v2.0, so you can see the shape of a reasonably complete file — and where you still have to ask.
| Document / attribute | Why an assessor wants it | Status for CellTrypase |
|---|---|---|
| Lot-specific Certificate of Analysis | Links your batch to tested values | Provided |
| Safety Data Sheet | Operator safety, waste handling | Provided |
| AOF / TSE-BSE declaration | Source-level control of animal-borne agents | Provided; animal-origin-free |
| Expression system and host | Residual-risk assessment of the production organism | Fusarium oxysporum gene expressed in Bacillus sp., GMO safety level S1 |
| Identity and purity | Confirms what you are actually dosing | ≥95% by HPLC; ~22 kDa serine protease, cleaves after Lys/Arg |
| Activity with a stated unit definition | Makes lots comparable and dosing reproducible | 1x: 0.6–1.2 kU/L; 10x: 6–12 kU/L. 1 U = 1 µmol p-nitroaniline/min at 37 °C from 8 mM L-AAPA, pH 8.0 |
| Sterility | Bioburden control in an open step | Pass, Ph. Eur. 2.6.1 / USP <71> |
| Endotoxin | Pyrogen carryover into the cell product | ≤1 EU/mL (1x); ≤10 EU/mL (10x) |
| Mycoplasma | Adventitious agent control | Negative |
| pH and osmolality | Physiological compatibility at the dissociation step | pH 7.1–7.6; 270–320 mOsm/kg |
| Full formulation disclosure | Every excipient is a potential carryover | PBS with 1.1 mM EDTA, sterile filtered |
| Manufacturing quality system | Evidence the file will stay true next year | GMP grade: EXCiPACT® GMP/GDP. R&D grade: ISO 9001:2015 |
| Stability and shelf life | Supports your storage and expiry policy | At least 15 months at 2–8 °C; long-term study ongoing |
| Shipping excursion data | Justifies accepting ambient-shipped stock | Brief warm excursions reported not to affect activity |
| Change notification / quality agreement | You must hear about supplier changes before they reach you | Available for GMP-grade supply — agree scope and notice period in writing |
| Residual host cell protein and DNA | Carryover from the production organism | Request from supplier — not stated in PIS v2.0 |
| Container-closure and extractables data | Leachables into an open process step | Request from supplier |
| Drug Master File | Lets a filing reference the supplier's confidential data | Not yet on file. c-LEcta describes a DMF submission as part of its regulatory roadmap. Confirm current status directly before building a submission around it |
What the performance data covers — and what it does not
Documentation completeness and performance evidence are different things, and it is worth being blunt about the second. c-LEcta reports application data for four production cell lines only:
| Cell line | Release time (min:s) | Viability | Yield |
|---|---|---|---|
| CHO-K1 | 2:25 | 98% | 106% |
| HEK 293 | 2:27 | 95% | 100% |
| Vero | 4:07 | 99% | 103% |
| MDCK | 23:32 | 99% | 102% |
Source: c-LEcta PIS CellTrypase v2.0. The MDCK release time is roughly ten times that of HEK 293 — shown here because you need it for scheduling, not despite it.
For a cell and gene therapy audience, the honest statement is this: there is no published performance data for the cell types most of you actually work with. Induced pluripotent stem cells, organoids, primary cells, neurons, mesenchymal stromal cells, T cells, cardiomyocytes and RPE are listed by the manufacturer as intended applications. No viability, yield, recovery, replating efficiency, proliferation, pluripotency-marker or surface-epitope retention figures are published for any of them.
If a supplier tells you otherwise, ask which study, which passage, which assay. For a CAR-T or MSC process, surface-marker retention after dissociation is a release-relevant attribute, and it is not something to take on trust from a datasheet that does not measure it.
Moving from R&D grade to GMP grade without surprises
CellTrypase is supplied in two grades from the same manufacturing platform: R&D grade under ISO 9001:2015, and GMP grade under EXCiPACT® GMP/GDP certification. The attraction is obvious — develop on the cheaper grade, transfer to the certified grade for clinical manufacture, and keep the enzyme constant across the transition.
Two cautions, both real.
First, a grade change is still a change. Substituting an ancillary material — even for a nominally identical product at a higher grade — is a change-control event that your quality system governs. No supplier statement can waive your own comparability assessment, and you should be suspicious of any that appears to. The scale of the exercise is proportionate to risk, not automatically large, but it is never zero.
Second, plan the comparability work rather than assume it. There is precedent for doing this properly: a published case study transitioning an MSC expansion process from research-use-only to GMP-grade ancillary material demonstrated no statistically significant differences in harvest yield, doubling time, seeding efficiency or fold expansion, and confirmed ISCT marker criteria after transfer (Frank et al., Cytotherapy 2025). Note what that study did: it measured equivalence rather than asserting it. That is the model to copy.
Related to this, be aware of the concentration formats. The 10x concentrate is materially cheaper per millilitre of working solution, but diluting it adds an open manipulation and a diluent you must qualify. In a GMP suite that trade-off often favours the ready-to-use 1x format despite the higher unit price.
A practical qualification sequence
- Request the document pack from the table above, including the three items marked “request from supplier”. Note what arrives and what does not.
- Map the file against your filing regions — Ph. Eur. 5.2.12 and USP <1043> expect different things; ISO 20399:2022 helps you frame the supplier conversation.
- Run a bench comparison on your own cells. A free 100 mL sample is available for qualification and process development. Record release time, viability, recovered cell number, and the endpoints that matter for your product — marker expression, potency, and behaviour over the following two passages.
- Confirm at scale-down in your actual vessel format before committing.
- Raise the change control, with the comparability data attached. Agree the change-notification scope with the supplier in writing at the same time.
Dosing carries over directly — approximately 1 mL per 25 cm², pre-warmed, with activity quenched by dilution in buffer or medium rather than by a separate inhibitor. Treat that as dosing guidance only: verify detachment time and viability in your own cell model before switching.
For the handling detail, see the CellTrypase dissociation protocol; for the full attribute list, the CellTrypase specification guide. Cell models are listed under cell lines, and process quantities or documentation packages can be scoped via a quote request.
References
- Tanaka M, et al. Comparison of guidelines for biological ancillary materials used for the manufacture of gene and cellular therapy products. Cytotherapy 2022. doi:10.1016/j.jcyt.2022.09.005
- Atouf F. Cell-based therapies formulations: unintended components. AAPS J 2016. doi:10.1208/s12248-016-9935-9
- Jere D, et al. Challenges for cell-based medicinal products from a pharmaceutical product perspective. J Pharm Sci 2020. doi:10.1016/j.xphs.2020.11.040
- Frank ND, et al. Good Manufacturing Practice-grade fibronectin for hollow-fiber bioreactor cell manufacture: a mesenchymal stromal cell case study. Cytotherapy 2025;27(3):391–9. doi:10.1016/j.jcyt.2024.11.011
- Farshid M, et al. The clearance of viruses and transmissible spongiform encephalopathy agents from biologicals. Curr Opin Biotechnol 2005;16(5):561–7. doi:10.1016/j.copbio.2005.07.006
- European Pharmacopoeia general chapter 5.2.12, Raw materials of biological origin for the production of cell-based and gene therapy medicinal products.
- USP General Chapter <1043>, Ancillary Materials for Cell, Gene, and Tissue-Engineered Products.
- ISO 20399:2022, Biotechnology — Ancillary materials present during the production of cellular therapeutic products and gene therapy products.
- c-LEcta GmbH. Product Information Sheet, CellTrypase v2.0.
Figures 1–3 are illustrative summaries prepared by BioHippo from the c-LEcta Product Information Sheet CellTrypase v2.0 and the cited literature; they are not experimental data. Literature identified via PubMed. Pharmacopoeial and ISO chapters are cited by title; consult the current official text for binding requirements. TrypLE™ is a trademark of Thermo Fisher Scientific Inc. It is referenced here only to identify a widely used class of recombinant dissociation reagent; no affiliation with, sponsorship by or endorsement from Thermo Fisher Scientific is implied. R&D-grade CellTrypase is supplied For Research Use Only (RUO) and is not for use in diagnostic or therapeutic procedures. GMP-grade material is supplied as a processing aid for biopharmaceutical manufacturing and is not for direct administration to humans or animals.
